Long-term data on ambulatory monitoring patches. Scientists from the Scripps Research Translational Institute and Johnson & Johnson have unveiled three-year study data for iRhythm Technologies' Zio wearable ambulatory monitoring patches at this year's American Heart Association Scientific Sessions. The mSToPS study examined 1,738 participants who were a mean age 73.7 years at the time of...
iRhythm Technologies, maker of the Zio XT and Zio AT adhesive heart monitors, announced first quarter financials boasting higher revenue and an improved gross margin during an earnings call for investors earlier this week. These promising numbers were paired with a net loss nearly double what was reported last year during the same quarter, although these were waved off by executives as the result...
Patients at increased risk for atrial fibrillation wearing iRhythm’s Zio patch — a continuous ECG monitoring wearable — were more likely to have their atrial fibrillation diagnosed early and receive subsequent preventive care, according to one-year results from a late-breaking study presented at the American College of Cardiology’s annual meeting.
The mHealth Screening to Prevent Strokes (...
Chinese medical supply company Shenzen-Kingyield has received FDA 510(k) clearance for a Bluetooth-connected blood pressure monitor. The device is worn on the wrist and sends data to a smartphone for archiving or analysis, according to the clearance document, and the device has been cleared for over the counter sales. The company makes a variety of blood pressure monitors, blood glucose monitors...
iRhythm, maker of the wearable-and-wireless-but-not-connected Zio heart rate monitoring system, has filed with the SEC to raise up to $86 million in an initial public offering.
The Zio patch, iRhythm's sole product as of now, is a small wearable sensor, used for multi-day monitoring of arrhythmias in cardiac patients (up to a fortnight). Unlike many participants in that space, however, the...
The Scripps Translational Science Institute is working with Aetna and Johnson & Johnson to launch a trial that will test iRhythm's Zio Patch and the Amiigo activity tracker as possible new ways to screen at-risk populations for atrial fibrillation.
"What we really want at the end of this study is to be able to best understand what the right way is to screen high-risk patients for atrial...
iRhythm Technologies, maker of the Zio peel-and-stick wearable heart monitor, has launched a patient-facing companion app on iOS, called myZio, as well as a website, called myZio.com. The app and website allow wearers to track additional health data. They don't display data collected by the Zio patch.
These are the first patient-facing data offerings that the company, which commercially launched...
iRhythm Technologies, maker of the Zio patch peel-and-stick heart monitor, has raised $17 million in a round led by Novo A/S, a Danish life sciences investment firm. Previous investor Norwest Venture Partners also participated in the round. This brings the company's total disclosed funding to about $85 million, based on SEC filings and company announcements. As part of the latest investment deal...
Aetna will now reimburse for iRhythm's ZIO Patch, a continuous long-term heart monitor worn on an adhesive patch. The insurer recently updated its Clinical Policy Bulletin on cardiac event monitors, upgrading the ZIO Patch from "experimental and investigational" to "medically necessary" for certain conditions.
In particular, Aetna will reimburse for the ZIO Patch either "to evaluate syncope or...
A new study from the Scripps Translational Science Institute, published in the American Journal of Medicine, shows that iRhythm's Zio patch, a wireless adhesive heart monitor patch, detects more arrhythmia events than a traditional Holter monitor and provides a better experience for patients.
The study of 146 patients with mild atrial fibrillation compared the two devices over the length of time...
